Quantity of eligible patients: CDEC discussed the uncertainty in the amount of individuals with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some clients that are categorized as obtaining gentle or moderate sickness can have a critical bleeding phenotype,